Summary characteristics of articles included in the systematic review

Study characteristicsNumber (%)
 Cohort (n=55), n (%)54 (98.2)
 Case control (n=55), n (%)1 (1.8)
 Prospective (n=54), n (%)32 (58.2)
 Multicentre (n=55), n (%)19 (34.5)
 Aim of study to assess TTE (n=55)29 (52.7)
Patient characteristics
 Number of haemodynamically stable patients with TTE (n=53), n17 090
 Number of haemodynamically stable patients with TTE per study (n=53), median (IQR)179 (96–462)
 Female study patients (n=52), n (%)8975 (52.8)
 Male study patients (n=52), n (%)8036 (47.2)
 Number of patients with RVD (n=44), n (%)5399 (37.8)
 Number of patients with no RVD (n=44), n (%)8889 (62.2)
Geographic region (n=55)
 Asia/Oceania13 (23.6)
 Europe31 (56.4)
 Americas11 (20.0)
PE risk group in study (n=55)
 Low and intermediate risk44 (80.0)
 Intermediate risk5 (9.1)
 All risk6 (10.9)
RVD definition (n=55)
 Composite RVD definition37 (67.3)
 Individual variable RVD definition18 (32.7)
Time to TTE (n=40)
 ≤24 h11 (27.5)
 ≤48–72 h29 (72.5)
Primary outcome studied (n=55)
 Combined adverse events31 (56.4)
 All-cause mortality19 (34.5)
 PE-related mortality5 (9.9)
Outcomes studied (n=55)
 Combined adverse events37 (45.7)
 All-cause mortality27 (33.3)
 PE-related mortality17 (21.0)
Follow-up (n=55)
 In hospital or <14 days31 (56.3)
 14–30 days24 (43.7)

High-risk patients are defined by the presence of haemodynamic instability, intermediate-risk patients are haemodynamically stable but have a simplified pulmonary embolism severity index of >0 and may have evidence of right ventricular dysfunction (RVD) or positive cardiac biomarkers. Low-risk patients are defined as being haemodynamically stable with no evidence of RVD or abnormal cardiac biomarkers [3]. IQR: interquartile range; PE: pulmonary embolism; TTE: transthoracic echocardiogram.